博士論文

Suppression of acute active experimental allergic encephalomyelitis in Lewis rats with a mycophenolic acid derivative

（ミコフェノール酸誘導体によるルイスラット急性実験的アレルギー性脳脊髄炎の抑制効果の検討）

東北大学大学院医学研究科病態科学系専攻

（病態神経学講座）

溝 渕 雅 広

博士論文

Suppression of acute active experimental allergic encephalomyelitis in Lewis rats with a mycophenolic acid derivative

（ミコフェノール酸誘導体によるルイスラット急性実験的アレルギー性脳脊髄炎の抑制効果の検討）

東北大学大学院医学研究科病態科学系専攻

（病態神経学講座）

溝　渕　雅　広

Abstract—Oral administration of ethyl O-[N-(*p*-carboxyphenyl-carbamoyl]-mycophenolate (CAM), a derivative of mycophenolic acid (MPA) and an inosine monophosphate dehydrogenase inhibitor, dose-dependently suppressed acute EAE in Lewis rats without exerting any serious adverse effects. A daily dose of 50 mg/kg of CAM almost completely abolished both the clinical disease and the inflammation in the CNS. In the CAM-treated rats, a weight loss and fluctuations of peripheral lymphocyte subsets were minimized. The CAM treatment was effective when started at the time of sensitization but ineffective when deferred till day 10. Furthermore, CAM reduced the percentage of CD4+CD45RC- cells in the peripheral blood. The only detectable adverse effect was moderate anemia but it was rapidly improved after withdrawal of the drug. This drug could be a useful adjunct for the long-term immunosuppressive therapy for inflammatory diseases of the CNS.

Various immunosuppressive regimens have been advanced for the treatment of multiple sclerosis (MS) but immunosuppressive therapies are often hampered by serious adverse effects (Mckhann 1990). In this paper, we propose the candidacy of mycophenolic acid (MPA) for a long-term immunosuppressive therapy for inflammatory CNS diseases such as MS, based on our observations on the efficacy of the drug in acute active experimental allergic encephalomyelitis (EAE), an animal model for MS (Arnason 1983).

In EAE, conventional immunosuppressive agents were effective in the dose of lymphocyte depression and have sever side effects such as bone marrow suppression or bacterial infection, and the cessation of the drug sometimes associated relapse of EAE (Minagawa et al. 1987).

MPA is an inhibitor of inosine monophosphate (IMP) dehydrogenase and it is known to have diverse biological activities such as antiviral, antifungal, antitumor and immunosuppressive effects (Mitsui and Suzuki 1969; Ohsugi et al. 1976; Eugui et al. 1991a). A paucity of adverse effects makes this drug attractive in the recent clinical trials for an organ transplantation (Sollinger et al. 1992) and rheumatoid arthritis (Goldblum 1993), but the application of the drug for CNS diseases has not yet been reported.

In the present study, we assessed the efficacy of the oral administration of ethyl O-(N-(*p*-carboxyphenyl)-carbamoyl)-mycophenolate (CAM), one of MPA derivatives, in acute active EAE in Lewis rats by monitoring the clinical score, phenotypes of mononuclear cell in the peripheral blood and cellular infiltrates in CNS lesions, and myelin basic protein (MBP)-specific proliferation response of regional lymph node cells.

Materials and Methods.

Induction and clinical assessment of EAE.

Eight to nine week-old female Lewis rats were purchased from Charles River Japan, Inc. (Kanagawa, Japan). Rats were subcutaneously injected with

0.16 ml of inoculum in the bilateral foot pads. Each inoculum consisted of 8 mg of guinea pig spinal cord homogenate in 0.08 ml of saline emulsified with an equal volume of CFA containing 10 mg/ml of heat-killed *Mycobacterium tuberculosis* (H37Ra, Difco, Detroit, Michigan). For 28 days after the immunization, neurological signs were daily scored as follows: 0-normal, 1-flaccid tail, 2-hindlimb weakness, 3-hindlimb paralysis, 4-quadriplegia, 5-moribund or death.

CAM treatment.

In total of 55 rats were used under the guide lines set by the Animal Experiment Committee of Tohoku University School of Medicine. Five each of immunized rats were given 50 mg/kg, 30 mg/kg or 10 mg/kg of CAM in 0.5% carboxymethyl cellulose (CMC) solution once a day with a gastric tube. CAM was provided by Ajinomoto Co., Inc. (Tokyo, Japan). The drug is known to be absorbed from the small intestine and converted to MPA in mucosal cells (Matsuzawa and Nakase 1984). The control EAE rats received isovolume of 0.5% CMC solution. Two sets of experiments were performed. In the first experiment, the rats were treated with CAM from day 0, the day of immunization, to day 28 (CAM-1) and in the second experiment from day 10 to day 28 (CAM-2).

Preparation of mononuclear cell (MNC) fractions from the peripheral blood.

Blood samples, 0.9 ml per rat, were collected by a cardiac puncture under ether anesthesia between 1:00 p.m. and 3:00 p.m. on days -1, 4, 9, 11, 14, 17, 20, 28. The hematocrit was measured by the microhematocrit method, and total number of WBC was enumerated with a counting chamber. Differential WBC count was measured with a FACScan (Becton-Dickinson, Sunnyvale, CA) after lysing RBC with a lysing solution (Becton-Dickinson).

For phenotypic analysis of MNCs, blood samples were mixed with an equal volume of PBS. The mixtures were centrifuged through a Ficoll-Paque gradient (Pharmacia LKB, Uppsala, Sweden) at 400 × g for 5 min, and then at 1,200 × g for 12 min. MNCs were recovered from the plasma/Ficoll-Paque interface.

Isolation of cellular infiltrates from the CNS tissue.

Cellular infiltrates in the CNS tissue were collected on day 13 from the non-treated rats and the rats treated with 50 mg/kg and on day 15 from the rats treated with 30 mg/kg in CAM-1 experiment. Infiltrating cells were isolated by the method of Clatch et al. 1990 with minor modifications. In brief, after transcardial perfusion with saline, the spinal cord was removed and each spinal cord was separately processed. The tissue was dissociated through a 212 μm stainless steel screen, and the filtrates were centrifuged at 400 × g for 10 min. Each sediment was resuspended in 5 ml of 68% Percoll (Pharmacia) in PBS, and the mixture was overlaid with 3 ml of 30% Percoll in PBS. After centrifugation at 1200 × g for 30 min at 25 ℃, MNCs were recovered from 30%/68% Percoll interface.

Flow cytometric analysis.

MNCs suspended in PBS were aliquoted into 100 μl, 5×10^5 cells each, and were dually labeled with the following monoclonal antibodies in combination of CD4 and CD45RC or CD8 and CD3. Phycoerythrin-conjugated W3/25 for CD4, phycoerythrin-conjugated OX-8 for CD8, FITC-conjugated OX-22 for CD45RC were purchased from Serotec Ltd. (Blackthorn, UK) and FITC-conjugated 1F4 for CD3 from Caltag Lab. (San Francisco, CA). The cells were incubated with the antibodies for 45 min at 4 ℃, and washed with three changes of PBS, and then diluted for the FACScan analysis. Forward and side scatter gates were set for lymphocytes to exclude monocytes and RBC residues, and 10,000 cells were analyzed for each fraction.

MBP-specific proliferation assay.

The proliferative response to MBP of MNCs isolated from regional lymph nodes was assayed with the colorimetric MTT (tetrazolium) assay kit (Chemicon Int. Inc, Temecula, CA) (Mosmann 1983). On the day 12, MNCs were isolated from bilateral regional lymph nodes of the rats treated with 50 mg/kg of CAM from day 0. As controls, lymph node cells were collected from the control EAE rats and the rats treated with CFA without spinal cord homogenate. The isolated

cells were seeded in 96-well flat bottom plates at a density of 0.7×10^5 viable cells in 0.1 ml of RPMI 1640 medium supplemented with 10% FCS. The culture was prepared in triplicate. After incubation for 72 hrs at 37 ℃ without or with MBP at concentrations of 50, 10, and 1 μg/ml, 0.01 ml of MTT (5 mg/ml) was added to each well, and further incubated for 4 hrs. Before measurement, formazan crystals were solubilized with 0.1 ml acid-isopropanol. The amount of reaction product was mesured with MTP-32 microplate reader (Corona Electoric, Japan) at 575 nm and a reference wavelength of 630 nm. The results were expressed as stimulation index (SI) = $OD_{575-630}$ of stimulated culture / $OD_{575-630}$ of unstimulated culture. Statistical analysis was performed by the Student's t-test for two independent means.

Determination of the plasma concentration of MPA.

The temporal change of the plasma concentration of MPA, a bioactive metabolite of CAM, was determined by the HPLC method. Two, six and 24 hrs after a single oral administration of 50 mg/kg of CAM, 250 μl each of blood was transcardially obtained from 8 rats under ether anesthesia. A mixture of 0.1 ml of the plasma sample and 0.4 ml of methanol was centrifuged at 3,000 × g for 5 min, and 50 μl of the supernatant was applied to the HPLC system (Hitachi Inc., Japan) with a YMC-pack ODS-A A-303 column (YMC Co., Japan) at a flow rate of 1.0 ml/min with 0.1% TFA CH_3CN and H_2O (7:3) as a mobile phase. The effluent was monitored at a wavelength of 254 nm with a UV-detector (Shimadzu, Co., Japan).

Results.

Amelioration of clinical disease.

Control EAE rats inevitably developed flaccid tail on day 10 or 11 and limb paralysis by day 13 (closed circle in Fig. 1). In CAM-1 experiment started on day 0 (upper panel in Fig. 1), a daily dose of 10 mg/kg had little effects on both the onset and clinical score (3.0 vs. 3.4 in controls), but with a dose of 30

mg/kg, an average day of onset was delayed (13.4 vs. 10.2) and the maximum clinical score was reduced to 1.5. With a dose of 50 mg/kg, no rats developed limb paralysis, and only slight weakness of tail was suspected on day 12 (clinical score < 1). If the CAM treatment was deferred till day 10 (CAM-2), clinical manifestations of the disease were indistinguishable from those of control EAE rats (lower panel in Figs. 1).

Control EAE rats lost an average of 16% of body weight by day 15. It was reduced to -9% with a dose of 30 mg/kg, and with a dose of 50 mg/kg, no weight loss was evident (upper panel in Fig. 2). In CAM-2 experiment, however, the weight loss in the rats treated with 50 mg/kg of CAM was similar to that of control EAE rats (lower panel in Fig. 2).

Alterations of hemogram (Fig. 3).

By day 4, WBC count in control EAE rats was almost double of that on day -1, and they decreased with the development of neurological signs on day 11 to 14. The initial leukocytosis and lymphocytosis, however, were largely abolished in the rats treated with 50 mg/kg in CAM-1 experiment. Similar changes were seen in the rats received 10 mg/kg in CAM-1 experiment (data not shown) and 50 mg/kg in CAM-2 experiment. Moderate anemia developed in the rats received 50 mg/kg of CAM but it was normalized after cessation of the treatment.

Alterations of peripheral lymphocyte subsets (Fig. 4).

In control EAE rats, concomitant with the development of the clinical disease, the percentage of CD3 cells decreased significantly. The reduction of CD3 cells was coincided with a decrease of CD4 cells and a reciprocal increase of CD8 cells. The reduction of CD4 cells before the peak of the disease was normalized as the disease progressed. The reciprocal increase of CD8 cells was due to an increase in the percentage of CD3-CD8+ cells, possibly natural killer cells, but not of CD3+CD8+ cells.

In the EAE rats treated with 50 mg/kg of CAM from day 0 (CAM-1), the fluctuations of peripheral lymphocytes were largely abolished, but similar

fluctuations were seen in the rats treated from day 10 (CAM-2). Furthermore, the percentage of CD45RC- cells in the CD4 subset was gradually decreased from 50% on day -1 to 14% on day 14 in the rats treated with 50 mg/kg of CAM from day 0 (CAM-1). A similar tendency was seen in CAM-2 experiment but it was less remarkable.

Cellular infiltrates in the CNS tissue (Fig. 5, table).

At the height of the clinical disease, approximately 2 × 10^6 MNCs were recovered from the CNS tissue of control EAE rats, and the majority of these MNCs were lymphocytes. In the CAM-1 experiment, the number of cellular infiltrates was dose-dependently reduced, but it was much less effective in CAM-2 experiment. In the CAM-1 experiment, with a dose of 30 mg/kg, the number of MNCs was reduced to $0.99 \pm 0.43 \times 10^6$ vs. $2.06 \pm 0.49 \times 10^6$ in controls, and that of lymphocytes was $0.69 \pm 0.36 \times 10^6$ vs. $1.79 \pm 0.45 \times 10^6$. With a dose of 50 mg/kg, only 0.1×10^6 MNCs were recoverd. In both control and CAM-treated EAE rats, the lymphocytes were dominated by CD4 cells, and more than 95% of the CD4 cells showed CD45RC- phenotype (Table).

MBP specific proliferation assay (Fig. 6).

At a concentration of 1 μg/ml of MBP, the mean SI was 1.54±0.13 for control EAE rats, 1.07±0.00 for the rats treated with CFA alone and 1.07±0.02 for CAM-treated EAE rats. At a concentration of 50 μg/ml, SI was 1.87±0.14 for control EAE rats and 1.29±0.04 for CAM-treated EAE rats. The difference was significant between the control and CAM-treated rats.

Plasma level of MPA.

MPA was a major metabolite of CAM detected by this method. The plasma concentrations of MPA after a single oral administration of 50 mg/kg of CAM were 16.4 ± 7.1 mM (mean ± SD, n=8) at 2 hrs, 22.5 ± 9.0 mM at 6 hrs, and 2.5 ± 2.0 mM at 24 hrs.

Discussions.

CAM effectively suppressed acute EAE in Lewis rats. Amelioration of the clinical disease was associated with a marked reduction of the number of cellular infiltrates in the CNS tissue, and both the amelioration of the clinical disease and the reduction of cellular infiltrates in the CNS were achieved dose-dependently. The rats were not only protected from the development of EAE but a weight loss, commonly seen in EAE, was also absent during a four-week CAM treatment, further indicating a paucity of general toxicity of the drug.

The drug action of MPA is apparently multifactorial. The CAM treatment completely abolished leukocytosis, largely due to granulocytosis, in acute phase of EAE. This suppression of acute inflammatory response is likely to be mediated by the action of MPA on monocyte lineage cells since it is reported that at a concentration of 0.1 μ M, MPA suppresses differentiation of human promonocytes, possibly leading to the down-regulation of cytokine production, and augments the production of IL-1ra, an IL-1 receptor antagonist, in human peripheral monocytes (Waters et al. 1993). In the present study, the plasma level of MPA was higher than 2 μ M even at 24 hrs after a single oral administration of 50 mg/kg. This would be sufficient to suppress the cell differentiation and the production of cytokines in monocyte lineage cells. The general suppression of acute inflammatory reaction may also affect the generation of MBP-specific lymphocytes in the regional lymph nodes.

The fluctuation in the number of peripheral lymphocytes in control EAE rats was indistinct in the CAM-treated rats. Control EAE rats developed mild lymphopenia concomitant with the development of the clinical disease. This is due to reduction of CD3 cells accompanied by a moderate decrease of CD3+CD4 subset, a slight reduction of CD3+CD8+ cells and a reciprocal increase of CD3-CD8+ cells, NK cells. This lymphopenia is generally thought to be secondary to the accumulation of lymphocytes in the CNS lesions. If this is the case, the absence of lymphopenia in the CAM-treated EAE rats could be explained by abrogation of inflammation in the CNS.

Now, it would be worth to note that during the entire course of EAE, the numbers of CD3 cells, CD4 cells and CD8 cells were remarkably stable in the rats treated with 50 mg/kg of CAM for 4 weeks from day 0 (CAM-1) where the clinical disease was almost completely abolished. The observation may suggest that CAM selectively suppresses clonal expansions of the cells stimulated with new antigens without disturbing the kinetics of other cell populations. In support of this view, it is suggested that MPA does not interfere early responses of T and B lymphocytes to mitogenic or antigenic stimulation but only blocks the cells at the time of DNA synthesis (Eugui et al. 1991b). This unique drug action seems to be related to the preferential inhibition of inducible type II IMP dehydrogenase by MPA (Carr et al. 1993) since type II IMP dehydrogenase dominates in activated cells and neoplastic cells while type I IMP dehydrogenase is the main species in normal cells (Konno et al. 1991), and it can be up-regulated by mitogenic and antigenic stimulations (Nagai et al. 1992).

The only noticeable change in lymphocyte subsets in the CAM-treated rats was a steady decline of the percentage of CD45RC- population, most conspicuous in the CD4 subset. This phenomenon could be explained by the type specific inhibition of type II IMP dehydrogenase since CD4+CD45RC- cells are thought to be memory/activated T cells (Ericsson et al. 1991) and the decrease of this subpopulation of T cells is likely to be reflecting an inhibition of proliferation of stimulated lymphocytes. A low recovery rate of MBP-reactive cells from the regional lymph nodes in the CAM-treated rats in the absence of a significant loss of total lymph node cells could support this possibility. The reduction of CD4+CD45RC- cells was also seen in non-immunized rats treated with CAM for more than 2 weeks (data not shown), and it was normalized within 2 weeks after withdrawal of the drug, suggesting non-specificity and reversibility of the phenomenon. Such a non-specific reduction of CD4+CD45RC- cells may be beneficial for the suppression of inflammatory CNS diseases. At least in the CNS lesions of EAE, more than 70% infiltrating CD3

lymphocytes and over 95% of CD4 cells are of this phenotype, and only a small minority of the cells are MBP-reactive and the majority is stimulated by antigens irrelevant to EAE (Cohen et al. 1987).

When the CAM treatment was deferred till day 10, little beneficial effects were observed. Thus, the treatment appears to be effective only for induction phase although MPA may have a potential to suppress the influx of inflammatory cells into target tissues by blocking the glycosylation of adhesion molecules (Allison et al. 1993) and indeed the inflammation in EAE is abrogated by anti-VLA-4 antibody in this experimental model (Sako et al. 1993). The only adverse effect in the present study was anemia. The lowest Hct value in the EAE rats treated with 50 mg/kg of CAM was nearly half of control EAE rats but the rats rapidly recovered from anemia after withdrawal of the drug. A similar observation was made in non-immunized rats treated with 50 mg/kg of CAM for 3 weeks (data not shown). Thus, the suppression of the hematopoietic system by MPA seems to be reversible.

Unlike other immunosuppressive agents, MPA appears to exert little serious adverse effects, and it seems to be related to the type-specific inhibition of IMP dehydrogenase. Although much work needs to be done to elucidate the mechanism of immunosuppression such as the effects of the function of monocyte-macrophage cells, antigen presentation cells and adhesion molecules, and to establish an optimal protocol for clinical application of the drug, CAM can be considered as an attractive adjunct for the long-term treatment of inflammatory diseases of the CNS such as MS.

References

1) Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. (1993). Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. *Transplant Proc.* **25(suppl 2).** 67-70

2) Arnason BGW. (1983). Relevance of experimental allergic encephalomyelitis to multiple sclerosis. *Neurol Clin.* **1.** 765-782

3) Carr SF, Papp E, Wu JC, Natsumeda Y. (1993). Characterization of human type I and type II IMP dehydrogenases. *J Biol Chem.* **268.** 27286-27290

4) Clatch RJ, Miller SD, Metzner R, Dal Canto MC, Lipton HL. (1990). Monocyte/macrophages isolated from the mouse central nervous system contain infectious Theiler's murine encephalomyelitis virus (TMEV). *Virology.* **176.** 244-254

5) Cohen JA, Essayan DM, Zweiman B, Lisak RP. (1987). Limiting dilution analysis of frequency of antigen-reactive lymphocytes isolated from the central nervous system of Lewis rats with experimental allergic encephalomyelitis. *Cell Immunol.* **108.** 203-213

6) Ericsson PO, Linden O, Dohlsten M, Sjogren HO, Hedlund G. (1991). Functions of rat CD4+ T cell subsets defined by CD45RB; CD45RB- cells have a much stronger response to recall antigens, whereas polyclonally activated cells of both subsets are equally efficient producers of INF in the presence of exogeous IL-2. *Cell Immunol.* **132.** 391-399

7) Eugui EM, Mirkovich A, Allison AC. (1991a). Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. *Scand J Immunol.* **332.** 175-183

8) Eugui EM, Almquist SJ, Muller CD, Allison AC. (1991b). Lymphocyte-

selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro ; role of deoxyguanosine nucleotide depletion. *Scand J Immunol.* **33.** 161-173

9) Goldblum R. (1993). Therapy of rheumatoid arthritis with mycophenolate mofetil. *Clin Exp Rheumatol.* **11(suppl 8).** S117-119

10) Konno Y, Natsumeda Y, Nagai M et al. (1991). Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines. *J Biol Chem.* **266.** 506-509

11) Matsuzawa Y, Nakase T. (1984). Metabolic fate of ethyl O-[N-(p-carboxyphenyl-carbamoyl]-mycophenolate (CAM), a new antitumor agent, in experimental animals. *J Pharm Dyn.* **7.** 776-783

12) Mckhann GM. (1990). Therapeutic trials for multiple sclerosis. *Ann Neurol.* **27.** 589-590

13) Minagawa H, Takenaka A, Itoyama Y, Mori R. (1987). Experimental allergic encephalomyelitis in the Lewis rat - A model of predictable relapse by cyclophosphamide. *J Neurol Sci.* **78.** 225-235

14) Mitsui A, Suzuki S. (1969). Immunosuppressive effect of mycophenolic acid. *J Antibiotics.* **8.** 358-363

15) Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. *J Immunol Methods.* **65.** 55-63

16) Nagai M, Natsumeda Y, Weber G. (1992). Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. *Cancer Res.* **52.** 258-261

17) Ohsugi Y, Suzuki S, Takagaki Y. (1976). Antitumor and immunosuppressive effects of mycophenolic acid derivatives. *Cancer Res.* **36.** 2923-2927

18) Sako K, Iwasaki Y, Ohara Y, Tsunoda I, Okumura K. (1993). Anti-very

late antigen-4 antibody suppresses acute active experimental allergic encephalomyelitis in Lewis rats [abstract]. *J Neuropathol Exper Neurol.* **52.** 310

19) Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. (1992). RS-61443-A phase I clinical trial and pilot rescue study. *Tranplantation.* **53.** 428-432

20) Waters RV, Webster D, Allison AC. (1993). Mycophenolic acid and some antioxidants induce differentiation of monocytic lineage cells and augment production of the IL-1 receptor antagonist. *Ann N Y Acad Sci.* **696.** 185-196

Figure legends

Fig.1: Clinical score (n=5). A daily dose is shown by parenthesis. Note the dose-dependent amelioration in CAM-1 and a lack of efficacy in CAM-2.

Fig. 2: Body weight (n=5). The weight loss in control EAE rats is ameliorated in CAM-treated rats in CAM-1.

Fig. 3: Profiles of peripheral blood (50 mg/kg, n=5). Fluctuations of WBC and Lymphocyte counts in control EAE rats are largely abolished in CAM-treated rats in CAM-1.

Fig. 4: Peripheral lymphocyte subsets (n=5). Alterations of the percentage of T cell subsets in control EAE rats are less conspicuous in CAM-treated EAE rats, and a steady decline of the percentage of CD4+CD45RC- cells is also evident in the CAM-treated rats.

Fig. 5: Mononuclear cells recovered from the spinal cord (n=5). The numbers of MNCs and lymphocytes are substantially reduced in the rats treated with 30 mg/kg of CAM and they are hardly isolated from those treated with 50 mg/kg in CAM-1, but the treatment is barely effective in CAM-2.

Fig. 6: MBP-specific proliferating assay (triplicate, n=3). The cells were harvested on day 12. The MBP-reactive cells are apparently reduced in lymph node cells from CAM-treated rats.





Fig.1



Fig.2



Fig.3



Fig.4



Fig.5



* : Statistically significant

Fig.6

Table. Phenotypes of lymphocytes isolated from the spinal cord.

	CAM-1					CAM-2			
	control		CAM (30)		CAM (50)	control		CAM (50)	
	number ($\times 10^6$)	(%)	number ($\times 10^6$)	(%)	number	number ($\times 10^6$)	(%)	number ($\times 10^6$)	(%)
CD3	1.53±0.43	(84.5±2.9)	0.60±0.34*	(86.0±5.9)	<0.001*	1.42±0.36	(86.6±1.8)	1.18±0.49	(86.6±4.2)
CD4	1.12±0.35	(61.6±4.4)	0.45±0.26*	(64.1±9.7)	<0.001*	1.12±0.27	(68.8±3.1)	0.97±0.46	(69.6±11.4)
CD3-CD8+	0.02±0.01	(1.3±0.9)	0.01±0.00*	(1.5±0.8)	<0.001*	0.02±0.02	(1.5±0.9)	0.01±0.00	(0.6±0.2)
CD3+CD8+	0.33±0.09	(18.2±1.7)	0.13±0.08*	(18.9±5.2)	<0.001*	0.26±0.07	(15.9±2.6)	0.21±0.08	(16.6±7.8)
CD4+CD45RC-	1.10±0.35	(60.6±4.6)	0.44±0.26*	(62.9±10.2)	<0.001*	1.10±0.28	(67.4±2.7)	0.95±0.47	(67.8±12.3)
CD4+CD45RC- (in CD4+)		(98.2±0.5)		(98.0±1.5)			(98.0±1.3)		(97.1±2.2)

* $p<0.05$



Kodak Color Control Patches

© Kodak, 2007 TM: Kodak

Blue Cyan Green Yellow Red Magenta White 3/Color Black



Kodak Gray Scale

© Kodak, 2007 TM: Kodak

A 1 2 3 4 5 6 **M** 8 9 10 11 12 13 14 15 **B** 17 18 19